Do Wall Street Analysts Like IDEXX Laboratories Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Should l Buy IDXX?
Source: NASDAQ.COM
IDEXX Laboratories Overview: IDEXX Laboratories, a leader in pet healthcare with a market cap of $37.1 billion, has seen its stock decline 19.5% over the past year but rebound with a 12.2% increase year-to-date, outperforming the ProShares Pet Care ETF in 2025.
Financial Performance and Analyst Ratings: Following strong Q4 results with a 5.8% revenue increase, IDEXX expects organic revenue growth of 6%-9% for fiscal 2025; analysts have a consensus rating of "Moderate Buy," with a mean price target suggesting a potential upside of 12% to 22.1%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 570.210
Low
750.00
Averages
792.78
High
850.00
Current: 570.210
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of the Importance of Market Capitalization
- Market Capitalization Comparison: Dell Technologies Inc (DELL) has a market cap of $47.50 billion, while Idexx Laboratories, Inc. (IDXX) stands at $45.95 billion, providing investors with a more accurate assessment of company value and avoiding misconceptions based solely on stock price.
- Investor Decision Impact: Market capitalization not only affects a company's size ranking among peers but also directly influences which mutual funds and ETFs are willing to hold these stocks, as large-cap funds may focus solely on companies valued at over $10 billion.
- Mid-Cap Performance Potential: The S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, allowing mid-cap stocks to potentially outperform larger rivals in favorable market conditions, thus offering additional investment opportunities for investors.
- Price Performance Comparison: At Thursday's close, DELL's stock rose approximately 5.1%, while IDXX's stock increased by about 0.5%, indicating Dell's strong market performance, which may attract more investor attention to its growing market capitalization.
See More
Bullish Thesis on IDEXX Laboratories Stock Investment
- Strong Profitability: IDEXX Laboratories has demonstrated earnings per share growth ranking in the top 10% over recent quarters and years, highlighting its robust profitability amid rising pet healthcare spending, which attracts investor interest.
- Rising Market Demand: As pet owners increasingly seek advanced care, IDEXX's diagnostic business benefits from long-term growth in pet healthcare spending, which is expected to drive future revenue growth for the company.
- Outstanding Stock Performance: IDEXX's stock price has appreciated by 60.4% over the past 52 weeks, placing it among the top 10% on a relative strength basis, reflecting its sustained revenue growth and high-margin business model.
- Attractive Investment Opportunity: The company's strong financial performance in the pet healthcare sector and favorable demographic trends make IDEXX's stock an appealing choice for investors seeking exposure to structural growth.
See More
Bamco Inc Increases Stake in FactSet by $317.17 Million
- Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to an investment of $317.17 million, indicating confidence in the company despite a 58.2% decline in stock price over the past year.
- Asset Allocation: FactSet now accounts for 2.27% of Bamco's 13F assets under management, highlighting its significance in Bamco's investment portfolio, even as overall market performance remains weak.
- Financial Overview: FactSet's latest financial report shows a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, indicating the company's ability to maintain profitability under a stable subscription model.
- Market Position: As a leading provider of financial data and analytics, FactSet supports global investment decision-making through its comprehensive workflow solutions, reinforcing its role as a key partner for institutional investors despite facing market volatility challenges.
See More
Bamco Inc Increases Stake in FactSet Research Systems
- Stake Increase: Bamco Inc increased its stake in FactSet Research Systems by 1,069,786 shares during Q4 2026, bringing its total holdings to 2,888,845 shares valued at $838.31 million, indicating strong confidence in the company.
- Asset Management Proportion: This acquisition positions Bamco's holdings in FactSet at 2.27% of its 13F reportable assets under management, although it remains outside the top five holdings, highlighting its significance in the investment portfolio.
- Market Performance: As of February 17, 2026, FactSet's stock price stood at $190.06, down 58.2% over the past year, underperforming the S&P 500 by 69.8 percentage points, reflecting market concerns regarding its future growth prospects.
- Business Model Advantage: FactSet leverages a robust subscription model and comprehensive workflow solutions to continuously provide financial data and analytics to global investment professionals, ensuring stable revenue streams and strong client relationships despite market fluctuations.
See More
Bamco Expands FactSet Stake to $838 Million as Financial Data Platform Drives Recurring Revenue
- Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to $317.17 million, which now represents 2.27% of its 13F assets under management, indicating strong confidence in the financial data platform.
- Market Performance: As of February 17, 2026, FactSet shares were priced at $190.06, reflecting a 58.2% decline over the past year, significantly underperforming the S&P 500 by 69.8 percentage points, raising concerns about its future growth prospects.
- Financial Overview: FactSet reported a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, showcasing its stability and profitability in the financial data and analytics sector.
- Client Base: FactSet provides integrated financial information and analytics tools for global investment professionals, relying on its subscription model to generate recurring revenue, ensuring strong client retention, particularly among asset managers and investment banks.
See More
BAMCO Reduces Stake in Vail Resorts
- Share Reduction Details: According to a SEC filing dated February 17, 2026, BAMCO Inc sold 892,764 shares of Vail Resorts during Q4, reducing its holdings to 4,809,928 shares, with a quarter-end valuation decline of $214.19 million reflecting both trading activities and price movements.
- Asset Management Ratio Shift: Following this sale, Vail Resorts now represents only 1.73% of BAMCO's 13F reportable AUM, indicating investor concerns regarding the resilience of high-end vacation spending in an uncertain travel environment.
- Company Financial Overview: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, which reflects market caution regarding its future growth prospects.
- Profitability Model Analysis: Vail Resorts generates revenue primarily from lift ticket sales, lodging, and ancillary resort services; while the Epic Pass offers predictable cash flow, the company's high fixed costs mean that even slight declines in visitor numbers can significantly pressure earnings.
See More
Analysis of the Importance of Market Capitalization
- Market Capitalization Comparison: Dell Technologies Inc (DELL) has a market cap of $47.50 billion, while Idexx Laboratories, Inc. (IDXX) stands at $45.95 billion, providing investors with a more accurate assessment of company value and avoiding misconceptions based solely on stock price.
- Investor Decision Impact: Market capitalization not only affects a company's size ranking among peers but also directly influences which mutual funds and ETFs are willing to hold these stocks, as large-cap funds may focus solely on companies valued at over $10 billion.
- Mid-Cap Performance Potential: The S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, allowing mid-cap stocks to potentially outperform larger rivals in favorable market conditions, thus offering additional investment opportunities for investors.
- Price Performance Comparison: At Thursday's close, DELL's stock rose approximately 5.1%, while IDXX's stock increased by about 0.5%, indicating Dell's strong market performance, which may attract more investor attention to its growing market capitalization.
See More
Bullish Thesis on IDEXX Laboratories Stock Investment
- Strong Profitability: IDEXX Laboratories has demonstrated earnings per share growth ranking in the top 10% over recent quarters and years, highlighting its robust profitability amid rising pet healthcare spending, which attracts investor interest.
- Rising Market Demand: As pet owners increasingly seek advanced care, IDEXX's diagnostic business benefits from long-term growth in pet healthcare spending, which is expected to drive future revenue growth for the company.
- Outstanding Stock Performance: IDEXX's stock price has appreciated by 60.4% over the past 52 weeks, placing it among the top 10% on a relative strength basis, reflecting its sustained revenue growth and high-margin business model.
- Attractive Investment Opportunity: The company's strong financial performance in the pet healthcare sector and favorable demographic trends make IDEXX's stock an appealing choice for investors seeking exposure to structural growth.
See More
Bamco Inc Increases Stake in FactSet by $317.17 Million
- Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to an investment of $317.17 million, indicating confidence in the company despite a 58.2% decline in stock price over the past year.
- Asset Allocation: FactSet now accounts for 2.27% of Bamco's 13F assets under management, highlighting its significance in Bamco's investment portfolio, even as overall market performance remains weak.
- Financial Overview: FactSet's latest financial report shows a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, indicating the company's ability to maintain profitability under a stable subscription model.
- Market Position: As a leading provider of financial data and analytics, FactSet supports global investment decision-making through its comprehensive workflow solutions, reinforcing its role as a key partner for institutional investors despite facing market volatility challenges.
See More
Bamco Inc Increases Stake in FactSet Research Systems
- Stake Increase: Bamco Inc increased its stake in FactSet Research Systems by 1,069,786 shares during Q4 2026, bringing its total holdings to 2,888,845 shares valued at $838.31 million, indicating strong confidence in the company.
- Asset Management Proportion: This acquisition positions Bamco's holdings in FactSet at 2.27% of its 13F reportable assets under management, although it remains outside the top five holdings, highlighting its significance in the investment portfolio.
- Market Performance: As of February 17, 2026, FactSet's stock price stood at $190.06, down 58.2% over the past year, underperforming the S&P 500 by 69.8 percentage points, reflecting market concerns regarding its future growth prospects.
- Business Model Advantage: FactSet leverages a robust subscription model and comprehensive workflow solutions to continuously provide financial data and analytics to global investment professionals, ensuring stable revenue streams and strong client relationships despite market fluctuations.
See More
Bamco Expands FactSet Stake to $838 Million as Financial Data Platform Drives Recurring Revenue
- Stake Increase: Bamco Inc increased its position in FactSet Research Systems by 1,069,786 shares during Q4 2025, amounting to $317.17 million, which now represents 2.27% of its 13F assets under management, indicating strong confidence in the financial data platform.
- Market Performance: As of February 17, 2026, FactSet shares were priced at $190.06, reflecting a 58.2% decline over the past year, significantly underperforming the S&P 500 by 69.8 percentage points, raising concerns about its future growth prospects.
- Financial Overview: FactSet reported a trailing twelve-month revenue of $2.36 billion and a net income of $599.60 million, with a dividend yield of 2.14%, showcasing its stability and profitability in the financial data and analytics sector.
- Client Base: FactSet provides integrated financial information and analytics tools for global investment professionals, relying on its subscription model to generate recurring revenue, ensuring strong client retention, particularly among asset managers and investment banks.
See More
BAMCO Reduces Stake in Vail Resorts
- Share Reduction Details: According to a SEC filing dated February 17, 2026, BAMCO Inc sold 892,764 shares of Vail Resorts during Q4, reducing its holdings to 4,809,928 shares, with a quarter-end valuation decline of $214.19 million reflecting both trading activities and price movements.
- Asset Management Ratio Shift: Following this sale, Vail Resorts now represents only 1.73% of BAMCO's 13F reportable AUM, indicating investor concerns regarding the resilience of high-end vacation spending in an uncertain travel environment.
- Company Financial Overview: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, which reflects market caution regarding its future growth prospects.
- Profitability Model Analysis: Vail Resorts generates revenue primarily from lift ticket sales, lodging, and ancillary resort services; while the Epic Pass offers predictable cash flow, the company's high fixed costs mean that even slight declines in visitor numbers can significantly pressure earnings.
See More
